CLAIMS

1. Use of an immune checkpoint inhibitor in the manufacture of a medicament for the treatment of cancer, wherein the immune checkpoint inhibitor is to be administered simultaneously, separately or sequentially in combination with a single-stranded antisense oligonucleotide targeted to STAT3.

2. The use according to claim 1, wherein the immune checkpoint inhibitor is selected from: an anti-PD-L1 antibody or an antigen-binding fragment thereof; an anti-PD1 antibody or an antigen-binding fragment thereof; and an anti-CTLA-4 antibody or an antigen-binding fragment thereof.

3. The use according to claim 1 or claim 2, wherein the immune checkpoint inhibitor is selected from: MEDI4736, MPDL3280A, 2.7A4, AMP-714, MDX-1105, nivolumab, pembrolizumab, pidilizumab, BMS936559, MPDL3280A, tremelimumab and ipilimumab.

4. The use according to any one of claims 1 - 3, wherein the immune checkpoint inhibitor is MEDI4736.

5. The use according to any one of claims 1 - 4, wherein the single-stranded antisense oligonucleotide targeted to STAT3 does not inhibit STAT1, STAT4, or STAT6.

6. The use according to any one of claims 1 - 5, wherein the single-stranded antisense oligonucleotide targeted to STAT3 is AZD9150.

7. The use according to any one of claims 1 - 6, wherein the cancer is selected from: lung cancer, including non small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, hepatocellular carcinoma (HCC), head and neck cancer, including head and neck squamous cell carcinoma (HNSCC), and lymphoma, including diffuse large B-cell carcinoma (DLBCL).

8. The use according to claim 7, wherein the cancer cells express PD-L1.

9. The use according to any one of claims 1 - 8, wherein the cancer is PD-L1 positive.

10. The use according to any one of claims 1 – 9, wherein the immune checkpoint inhibitor is MEDI4736 and the single-stranded antisense oligonucleotide targeted to STAT3 is AZD9150.

11. The use according to claim 10, wherein between 1 mg/kg and 20 mg/kg MEDI4736, and between 1 mg/kg and 10 mg/kg AZD9150 is to be administered.

12. The use according to claim 11, wherein the treatment is to be administered every week, every 2 weeks, every 3 weeks, or every 4 weeks.

13. The use according to any one of claims 1 – 12, wherein the single-stranded antisense oligonucleotide targeted to STAT3 is to be administered before the immune checkpoint inhibitor.

14. The use according to claim 13, wherein the single-stranded antisense oligonucleotide targeted to STAT3 is to be administered at least one day before the immune checkpoint inhibitor is to be administered.

15. The use according to any one of claims 1 – 14, wherein the single-stranded antisense oligonucleotide targeted to STAT3 is AZD9150 and the immune checkpoint inhibitor is MEDI4736, and wherein AZD9150 and MEDI4736 are to be administered concurrently or at different times.

16**.** The use according to any one of claims 1 – 15, wherein (i) two immune checkpoint inhibitors and (ii) a single-stranded antisense oligonucleotide targeted to STAT3 are to be administered; wherein the two immune checkpoint inhibitors are MEDI4736 and tremelimumab, and the single-stranded antisense oligonucleotide targeted to STAT3 is AZD9150.

17. Use of a pharmaceutical composition which comprises an immune checkpoint inhibitor and a single-stranded antisense oligonucleotide targeted to STAT3 in association with a pharmaceutically acceptable diluent or carrier in the manufacture of a medicament for the treatment of cancer, wherein the medicament is to be administered to a patient in need thereof, wherein the patient has cancer.